Literature DB >> 1853582

Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area.

T Santantonio1, M C Jung, S Miska, G Pastore, G R Pape, H Will.   

Abstract

The sequence variability in the pre-C region of the hepatitis B virus (HBV) genome in the serum of 42 anti-HBe antibody positive carriers with chronic hepatitis B was studied by PCR and direct sequencing to determine prevalence and type of HBV pre-C mutants in a highly endemic area. Except for one, all patients were infected with viruses containing mutations in the pre-C region which prevent precore and e-antigen (HBeAg) expression: 33 were infected predominantly or exclusively with variants containing a stop codon; two had a mixture of wild-type and a pre-C stop codon mutant virus; three had precore variants with mutations of the pre-C initiation codon and two of them an additional stop codon; four had a frameshift mutation; and one had two stop codons. One patient was infected with viruses which contained a mutation creating an amino acid exchange which should not prevent precore and HBeAg expression. These data demonstrate that in an endemic area a higher prevalence and even broader spectrum of pre-C HBV mutants are found than has been recognized previously in anti-HBe positive patients with chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1853582     DOI: 10.1016/0042-6822(91)91022-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  18 in total

1.  In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.

Authors:  Richard A Heipertz; Thomas G Miller; Colleen M Kelley; William E Delaney; Stephen A Locarnini; Harriet C Isom
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

Review 2.  Quantitative molecular methods in virology.

Authors:  M Clementi; S Menzo; A Manzin; P Bagnarelli
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

3.  Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses.

Authors:  D K Clarke; E A Duarte; A Moya; S F Elena; E Domingo; J Holland
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

4.  Nucleotide sequence analysis of precore and proximal core regions in patients with chronic hepatitis B treated with interferon.

Authors:  T Laskus; J Rakela; D H Persing
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

5.  Evidence for a base-paired region of hepatitis B virus pregenome encapsidation signal which influences the patterns of precore mutations abolishing HBe protein expression.

Authors:  S P Tong; J S Li; L Vitvitski; A Kay; C Treépo
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

Review 6.  Precore/core region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Seung Yeon Do; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

7.  Prevalence of mutations in core promoter/precore region in Japanese patients with chronic hepatitis B virus infection.

Authors:  A Nagasaka; S Hige; M Marutani; I Tsunematsu; M Saito; Y Yamamoto; S Konishi; M Asaka
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

8.  Translation of the hepatitis B virus P gene by ribosomal scanning as an alternative to internal initiation.

Authors:  N Fouillot; S Tlouzeau; J M Rossignol; O Jean-Jean
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

9.  Prevalence of hepatitis virus infections in Albanian refugees.

Authors:  T Santantonio; S Lo Caputo; C Germinario; S Squarcione; D Greco; V Laddago; G Pastore
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

10.  Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B.

Authors:  T Laskus; J Rakela; M J Tong; D H Persing
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.